- CME Logo


  1. Abou-Jawde RM, Reed J, Kelly M, Walker E, Andresen S, Baz R, Karam MA, Hussein M. Efficacy and safety resluts with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 2006; 23 (2): 263-72.
  2. Abdelkefi A, Ladeb S, Torjman L et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2007; in press.
  3. Alexanian R, Haut A, Khan AU, Lane M, McLeövey EM, Migliore PJ, Stuckey WJ jr, Wilson HE. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208(9): 1680-5.
  4. Alexanian R, Barlogie B, Tucker S. High-dose glucocorticoid treatment int resistent myeloma  Ann Intern Med 1986; 105: 8-11.
  5. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma Blood 1992; 80: 887-890.
  6. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994, 330: 484-489.
  7. Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer 1984, 53: 583-588.
  8. Alexanian R, Salmin S, Bonnet J, Gehan E, Haut A, Wei K. A Combination chemotherapy for multiple myeloma. Cancer 1977, 40: 2765-2771.
  9. Anderson KC, Hamblin TJ, Traynor A. Management of multiple myeloma today. Semin Hematol 1999, 36(suppl 3): 3-8.
  10. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130-1136.
  11. Attal M, Harousseau JL, Facon T, Guilhot Fa, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myelome. N Engl J Med 2003; 349: 2495-2502.
  12. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108: 3289-3294.
  13. Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.
  14. Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61 (5): 631-8, discussion 639-40.
  15. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
  16. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310: 1353-1356.
  17. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoetic –cell transplantation for multiple myeloma. N Engl J Med 2006 a; 354: 1021-1030.
  18. Barlogie B,Tricot GJ, van Rhee F, et al. Longterm outcome results of the first tandem autotransplant trial for multiple Myeloma. Br J Haematol 2006 b; 135: 158-164.
  19. Bender JG, To LB, Williams S, et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematotherapy 1992; 1: 329-3419.
  20. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
  21. Bensinger WI, Buckner CP, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88: 2787-2793.
  22. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee S, Wilson J, Morrison B, Adams J, Schenkein D, Swift R. Phase I/II trial assessing Bortezomib and Melphalan combination therapy for the treatment of patients with replapsed or refractory multiple myeloma. J Clin Oncol 2006, 24 (6): 937-44.
  23. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-493.
  24. Berenson J, Crowley J, Barlogie B, Salmon S. Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple-myeloma patients. Blood 1998; 92 (suppl 1): 318a.
  25. Bergsagel DE. The role of chemotherapy in the treatment of multiple myeloma. F. Mandelli (ed): Multiple Myeloma Bailliere's Clin Hematol. International Practice and Research, 1986, 2986, Volume 8/Number 4:783-794.
  26. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Blade J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511-515.
  27. Bladé J. Rozman C, Montserrat E et al. Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). Eur J Cancer Clin Oncol 1986, 22: 1193-7.
  28. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for definition response, relapse and progression in multiple myeloma after high-dose therapy. Brit J Haem 1998, 102: 1115-23.
  29. Brice P, Marolleau JP, Pautier P, et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996; 22: 449-456.
  30. Bruno B, Rotta M, Patriarca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Eng J Med 2007; 356: 1110-1120.
  31. Buzaid AC, Durie BG. Management of refractory myeloma: a review. J Clin Oncol, 1988, 6: 889-905.
  32. Byrne JL, Carter GI, Bienz N, Haynes AP, Russel NH. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. Bone marrow transplant 1998, 22: 639-43, 1998.
  33. Case DC, Lee BJ, Clarkson BD. Improved survival in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M2-protocol Am J Med. 1977, 63: 897-903.
  34. Cunningham D, Paz-Ares L, Mitan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma . J Clin Oncol 1994; 12: 759-763.
  35. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivates. J Clin Oncol 2003; 21: 4444-4454.
  36. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau JL, Dmoszynska A, Yu Z, Olesnyckyj M, Zeldis J, Knich R. Study of Lenalidomid plus Dexamethasone versus Dexamethasone alone in relapsed or refractory multiple myeloma (mm): results of a phase 3 study (MM-010). ASH 47th annual meeting 2005. Abstract. Online gesehen am 10.08.2006. Autorin des Berichts: Prof. Dr. med.Monika Engelhardt, Universitätsklinik Freiburg.
  37. Dimopoulos M, Spencer A, Attal M, Prince HM et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-32.
  38. Dou QP, Smith DM, Daniel KG, Kazi A. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. Prog Cell Cycle Res 2003; 5: 441-446.
  39. Einsele H, Schafere HJ, Hebart H, Bader P, Meisner C, Plasswilm L, Liebisch P, Bamberg M, Faul C, Kanz C. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003; 121: 411-418.
  40. Einsele H: Multiples Myelom – Was gibt es Neues in der Behandlung? Prof. Dr. med. Hermann Einsele, Medizinische Klinik und Poliklinik II der Julius-Maximilians-Universität Würzburg, publiziert von der Arbeitsgemeinschaft Plasmozytom/Multiples Myelom im Herbst 2007, online gesehen am 1. Dezember 2007
  41. Femand JP, Chevret S, Ravaud P, et al. High-dose chemotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005-2009.
  42. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
  43. Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Björkstrand B, Bladé J, de Laurenzi A, de Vries T, Ljungman P, Michallet M, Reiffers J, Russel NH, Samson D, Schaefer UW, Schattenberg A,
  44. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, Donk NW, Verdonck LF. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18: 3031-7.
  45. Giles FJ. Treatment of refractory multiple myeloma with cytotoxic therapy and radiation therapy. G. Gahrton et BGM Durie (eds): Multiple Myeloma. Arnold, London, Sydney, Auckland 1996: 130-147, 1996.
  46. Guba SC, Vesole DH, Jagannath S, et al. Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant 1997; 20: 1-3.
  47. Glasmacher A, Haferlach T, Gorschlüter M et al. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma Leukemia, 1997, 11 (suppl 5): 22-26.
  48. Glasmacher A, Gieseler F, Schmidt-Wolf IGH. Vinorelbin, orales Idarubicin und Dexamethason (VRID) als Induktionstherapie sowie Interferon-alpha und Dexamethason als Erhaltungstherapie bei Patienten mit refraktärem multiplen Myelom. Therapieprotokoll Bonn 1998.
  49. Hari P, Pasquini MC, Vesole DH. New questions about transplantation in multiple myeloma. Oncology (Williston Park) 2006; 20: 1230-1242.
  50. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
  51. Hartmann 0, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantatation for solid tumors and lymphomas: hematologic recovery and costs. Ann Intern Med 1997; 126: 600-607.
  52. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950
  53. Jannagath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with replapsed and/or refractry multiple myeloma with less than optimal response to bortezomibe alone. Haematologica. 2006; 91 (7): 929-34.
  54. Katzel JA, Parameswaran H, Vesole DH et al. Multiple Myeloma: Charging Toward a Bright Future. A Cancer J Clin 2007; 57: 301-318.
  55. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90 (9): 1287-8.
  56. Knop S, Gerecke C, Topp MS t al. Lenalidomid, Adriamycin and Dexamathasone Chemotherapy (RAD) is Safe and Effective in Treatment of Relapsed Multiple Myeloma – First Results of a German Multicenter Phase I7II Trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: 408. The American Society of Hematology, 48th Annual Meeting, December 9-11 2006, in Orlando, Florida.
  57. Kropff M, Bisping G, Liebisch P, Sezer O, Einsele H, Straka C, Kröger N, Metzner B, Engelhardt M, Lang N, Hentrich M, Wolf H, von Schilling C, Salwnder H, Berdel W E, Kienast J. Bortezomib in combination with high-dose Dexamethasone and continuous low-dose oral Cyclophosphamide for relapsed multiple myeloma. 2005. ASH- 47th. Annual Meeting 2005, Abstract 2549.
  58. Kumar L, Vikram P, Kochupillai V. Recent advances in the management of multiple myeloma. Natl Med J India, 2006 Mar-Apr; 19 (2): 80-9.
  59. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006; 42 (11): 16–22. Epub 2006 Jun 5.
  60. Kyle RA, Vincent Rajkumar S. Treatment of multiple myeloma: an emphasis on new developments. Ann Med. 2006; 38 (2): 111-5.
  61. Lacy M, Gerzt M, Dispenzieri A et al. Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression and Survival. Blood (ASH Annual Meeting Abstracts 2006; 108: 798, The American Society of Hematology, 48th Annual Meeting, December 9-11 2006, in Orlando, Florida.
  62. Liebisch P, Peest D. Multiples Myelom. Leitlinie der Deutschen Gesellschaft für Hämatologie und Onkologie. Stand: Juli 2005.
  63. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, Donk NW, Verdonck LF. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18: 3031-7.
  64. Ludwig H, Strasser-Weippl K, Schreder M et al. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol 2007; 18: 64-70.
  65. Mateos MV, Hernandez JM, Hernandez MT et al.: Bortezomib plus Melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase ½ study. Blood 2006; 108: 2165-2172.
  66. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplantation 1998, 22: 835-843.
  67. Mileshkin L, Stark R, Day B et al. Development of neuropathy in patients with myeloma treated with thalidomide. Patterns of occurence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507-4514.
  68. Moehler TM, Neben K, Egerer G, Punzel M, Schmier J, Cremer F, Hillengass J, Goldschmidt H, Ho AD. Thalidomide and CED-Chemotherapy in patients with poor prognosis multiple myeloma. Blood 1999, 10 SI: 124a.
  69. Moehler TM, Hawighorst H, Neben K, Benner A, Hillengass J, Egerer G, Max R, Ho AD, Goldschmidt H, van Kaick G. Functional magnetic resonance imaging for detection and monitoring of bone lesions in multiple myeloma. Radiologe 2000; 40: 723-730.
  70. Moreau P, Garban F, Facon T et al. Long-term and updated results of the IJM9903 and IFM9904 protocols comparing autologous followed by reduced-intensity conditioning allogeneic transplantation and double transplant in high-risk de novo multiple myeloma. 33rd Meeting of the EBMT, Lyon France 2007, abstract 0281.
  71. Multiples Myelom – Handbuch zur Erkrankung und Behandlung. Veröffentlicht von International Myeloma Foundation, 2006. Seite 33-36.
  72. Munshi NC, Barlogie B, Desikan KR, Wilson C. Novel approaches in myeloma therapy. Semin Oncol 1999, 26: 28-34.
  73. Neben K, Hawighorst H, Moehler TM, Egerer G, Punzel M, van Kaick G, Ho AD, Goldschmidt H. Clinical response to Thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. Blood 1999; 10 SI: 124a.
  74. Onkologie 2006, besucht am 20.08.2006.
  75. Orlowski RZ, Peterson BL, Sanford B et al.: the Cancer and Leukemia Group B. Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301. Blood (ASH Annual Meeting Abstracts 2006; 108: 797, The American Society of Hematology, 48th Annual Meeting, December 9-11 2006, in Orlando, Florida.
  76. Palumbo A, Bringhan S, Petrucci MT et al. A Prospective, Randomized, Phase III-Study of Melphalan 200 mg/m2 (MEL 200) Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients. Blood (ASH Annual Meeting Abstracts) 2006 a; 108: 55. The American Society of Hematology, 48th Annual Meeting, December 9-11 2006, in Orlando, Florida.
  77. Palumbo A, Bringhen S. Caravita T et al. Oral melphalan plus thalidomide and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 b; 367: 825-831.
  78. Pönisch W. Therapieprotokoll Leipzig 1999. Prospektiv randomisierter Vergleich der Wirksamkeit einer zytostatischen Initialtherapie mit Bendamustinhydrochlorid und Prednison (BP) vs. Melphalan und Prednison (MP) mit oder ohne einer intermittierenden Prednisontherapie bei Patienten mit multiplem Myelom im Stadium II und III im Alter zwischen 18 und 80 Jahren, die für eine Hochdosistherapie mit Stammzelltransplantation nicht geeignet sind.
  79. Pönisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol 2002, 29 (4 Supl. 13): 23-6.
  80. Powles R, Cunningham D, Malpas J. et al. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: results after 5 _ years after accrual of the last patient. Blood 1997; 90 (Suppl. 1): 356a.
  81. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005; 80:1549-1551.
  82. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080.
  83. Reece DE, Masih-Khan E, Chen C et al. Lenalidomide (Revlimide®) +/- Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2006; 108: 3550, The American Society of Hematology, 48th Annual Meeting, December 9-11 2006, in Orlando, Florida.
  84. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Assessment of proteasome inhibition for extending remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352 (24): 2546-8.
  85. Richardson PG, Blood E, Mitsiades CS, Jannagath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyi M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomised phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 18 [epub ahead of print).
  86. Richardson P, Jagannath S, Colson K. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol 2006, 4 (5):1; discussion 8; suppl. 13.
  87. Rosinol L, Lahuerta AS, Sureda A, de la Rubia J, García-Laraña, Hernández-Garcia, Hérnandez-Ruíz B, Pérez-Simón JA, Bello JL, Carrera D, Peñarrubia MJ, Abella E, Léon C, Poderós C, García-Ruíz C, Besalduch J, Martinéz- Martinéz, Pérez-Fernández, Ribas P, Escalante F, San Miguel JS, Bladé J. Feasibility and efficacy of a planned second Transplant ("auto" or "mini-allo") intensification in patients with multiple myeloma (mm) not achieving complete remission (CR) or Near-CR with a first autologous transplant. Results from a spanish PETHEMA/GEM Study. ASH – 47th. Annual Meeting 2005. Abstract 425, gesehen am 20.08.2006.
  88. Richardson PG, Mitsiades C, Ghobrial I et al. Beyond single-agent bortezomib: Combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006 c 18: 598-608.
  89. Samson D, Volin L, Schanz U, Bosi A, Gahrton G. Feasibility and toxicity of interferon maintenance therapy after allogeneic transplantation for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 1996, 17: 759-62.
  90. Samson D. Principles of chemotherapy and radiotherapy Multiple Myeloma. Hrsg.: Gahrton G, Durie GM, Arnold, London, Syndey, Auckland, 1996: 108-129, 1996.
  91. San Miguel JF, Bladé JC, Garcia-Sanz, R. Treatment of multiple myeloma Haematologica 84: 36-58, 1999.
  92. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
  93. Singhal S, Metha J, Desikan R, Ayers D, Roberson P, Eddlemon P, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
  94. Sinha R, Lonial S. Novel treatment approaches for patients with relapsed and refractory multiple myeloma. Curr Treat Options Oncol 2006, 7(3): 246-57.
  95. Straka C, Hebart H, Adler-Reichel S, Werding N, Emmerich B, Einsele H. Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma. Oncology 2003; 65: 94-98.
  96. Streetly M, Jones RW, Knight R et al. An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed refractory myeloma. Blood 2003; 102: 236a (abstract 829). Thierry F, Verdonck LF, Vernant JP, Volin L. Allogeneic and syngeneic transplantation in multiple myeloma. VIIth International Multiple Myeloma Workshop, Stockholm, Sweden 1999, pp 54-55 (abstrl34).
  97. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
  98. Tricot G, Vesole DH, Jannagath S et al., Graf-versus-myeloma effect. Proof of principle. Blood 1996; 87: 1196-1198.
  99. Vacca A, Ribatti D, Presta M, Minischetti M, Irularo M, Ria R, Albini A, Bussolino F, Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 1999; 93: 3064-3073.
  100. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
  101. Vesole DH, Tricot G, Jagannath S, et al., Autotransplantats in multiple myeloma: What have we learned? Blood 1996; 88:838-847
  102. Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J, Salmon SE, Barlogie B. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a southwest oncology group phase II trial J Clin Oncol 1999, 17: 2173-2179
  103. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
  104. Wang M, Delasalle K, Thomas S et al. Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2006 a 108: Abstract 403. 48th Annual Meeting of the “American Society of Hematology”, December 9.-12., 2006 in Orlando, Florida
  105. Wang M, Knight R, Dimopoulos M et al. Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamathasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2006 b 108: 3553. 48th Annual Meeting of the “American Society of Hematology”, December 9.-12., 2006 in Orlando, Florida
  106. Yakoub-Agha I, Hulin C, Doyen C, Benboubker L, Voillat L, Bouabdallah, Guillerm G, Moreau P, Maloisel F, Stoppa AM, Pegourie B, Rodon P, Dib M, Casassus P, Slama B, Voog E, Jardel H, Collet P, Wetterald M, Peny AM, Mineur P, Duguet C, Zerbib R, Facon T, Mary Maladie JY, Sang D. A multicenter prospective randomized study testing non-inferioritiy of Thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: first results of the final analysis of the IFM 01-02 Study. ASH 47th. Annual meeting 2005, abstract 364, Online-Version. Gesehen am 10.08.2006.
  107. Zangari M, Tricot G, Zeldis J, et al. Results of phase I study of multiple myeloma patients who relapse after high dose chemotherapy. Blood 2001; 98: 775 a, abstract 3226.